< Terug naar vorige pagina

Publicatie

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

Tijdschriftbijdrage - Review Artikel

Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1 beta, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
Tijdschrift: Journal of Inflammation Research
ISSN: 1178-7031
Volume: 13
Pagina's: 141 - 149
Jaar van publicatie:2020
Trefwoorden:familial mediterranean fever, Canakinumab, anti-IL1 therapy
BOF-keylabel:ja
IOF-keylabel:ja
BOF-publication weight:2
CSS-citation score:1
Auteurs:International
Authors from:Higher Education, Hospital
Toegankelijkheid:Open